Advertisement

Organisation › Details
Origenis (Group)
Origenis GmbH is a privately held German biopharmaceutical company developing brain-penetrating highly selective small molecule medicines and diagnostics for a variety of neurodegenerative and neuroinflammatory diseases. Origenis leverages its unique capabilities in drug design, compound synthesis, and characterization to engineer a continuous stream of proprietary intellectual property (IP)-protected new chemical entities capable of permeating the blood-brain barrier. Origenis' approach has been validated by multiple partners resulting in a significant IP and R&D portfolio that ensures strong patent protection. *
![]() |
Start | 2005-11-01 splitoff (MBO) |
Predecessor | Morphochem (Group) | |
![]() |
Industry | drug discovery services |
![]() |
Person | Almstetter, Michael (Origenis 202012 Managing Director) |
Person 2 | Thormann, Michael (Origenis 200609 Managing Director) | |
![]() |
Region | Martinsried |
Country | Germany | |
Street | 19a Am Klopferspitz | |
City | 82152 Martinsried | |
Tel | +49-89-7801676-0 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | B: 11 to 50 (2014-11-01) |
* Document for »About Section«: Neuron23 Inc.. (12/16/20). "Press Release: Neuron23 Closes $113.5 Million Series A and B Financing led by Westlake Village BioPartners, Kleiner Perkins, and Redmile Group". South San Francisco, CA. | ||
Record changed: 2024-12-29 |
Advertisement

More documents for Origenis (Group)
- [1] Origenis GmbH. (5/28/24). "Press Release: OncoBone Ventures and Origenis Announce Partnership to Develop Novel Therapies for Cancer Bone Metastasis". Tübingen & Boston, MA....
- [2] T-Curx GmbH. (12/15/22). "Press Release: T-Curx GmbH Announces the Appointment of Thomas (Tom) Loeser as CFO and the Attendance at the JPM 41st Annual Healthcare Conference 2023 in San Francisco". Würzburg....
- [3] Neuron23 Inc.. (12/16/20). "Press Release: Neuron23 Closes $113.5 Million Series A and B Financing led by Westlake Village BioPartners, Kleiner Perkins, and Redmile Group". South San Francisco, CA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement

» top